Publication Online – November 2015 Print – May 2016
This clinical practice statement
focuses on clinical scenarios for four treatment settings for stage II and III
rectal cancer. First, it addresses appropriate neoadjuvant therapy and how it
is impacted by risk classification, distance from distal tumor edge to anal
verge and distance from radial tumor edge to edge of mesorectal fascia.
Second, the document looks how circumferential resection margin, risk
classification, distance from the anal verge and total nodal count effect
choice of adjuvant therapy. Third, treatment for medically inoperable patients
and the role of performance status, presence of local symptoms and distance
from the anal verge is discussed. Finally, the clinical practice statement
considers chemoradiation with or without boost in patients who sought to avoid
or refused abdominoperineal resection.
Read the executive summaryRead the full guideline
ResourcesRAND/UCLA Appropriate Method User’s ManualRadiation Therapy for Cancers of the Colon, Rectum and AnusGastrointestinal Cancer-Refresher 2017
Author SocietyAmerican Society for Radiation Oncology
ASTRO guidelines present scientific, health, and safety information and may reflect scientific or medical opinion. They are available to ASTRO members and the public for educational and informational purposes only. Commercial use of any content in this guideline without the prior written consent of ASTRO is strictly prohibited.